Skip to main content
Caplight Logo









Oral Genome

Oral Genome

Private
Carlsbad, CaliforniaHealthcare & Life Scienceshttps://www.oralgenome.com/

Last Round

SAFE

Jun 26, 2026

Est. Valuation

$375,000

Total Funding Raised

$110,000

Company Overview

Oral Genome is a biotechnology company that provides point-of-care salivary testing kits to analyze biomarkers for oral and systemic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Medical AI, Precision Medicine, Healthcare Analytics

Business Model

B2B

Customer Profile

Hardware Sales, Hardware + Subscription, Government Contracts

AI Layer

Application

Keywords

saliva testpoint-of-care testingoral health diagnosticschairside diagnosticsPOCTrapid diagnosticssalivary biomarkersdental technologydental technon-invasive testingoral-systemic healthpreventive healthcaremedical AImedical devicescomputer visiondirect-to-consumer testingDTC testingbiotechnology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Oral Genome Comparables

Compare Oral Genome with similar companies based on industry and business-model similarity.

Oral Genome comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Drūl
84%
Spectrum Solutions
79%
SuperTruth
77%

Oral Genome Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SAFEJun 26, 2026
StrategicMar 5, 2024
SeedDec 1, 2022
AcceleratorSep 10, 2021

Key People

Founding team and executive leadership

Tina Saw

Chief Executive Officer

Executive Team

Gorkey Vemulapalli

Chief Technology Officer

Executive Team

Benjamin Whitfield

Chief Financial Officer

Executive Team

Oral Genome Investors

Notable investors and investment history

Oral Genome investors
InvestorRounds
American Dental AssociationStrategic

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 17, 2025

    Received the 2025 Cellerant Best of Class Hygiene Award for oral care innovation.

  • Nov 7, 2025

    Michael Shuman appointed as the new Chief Revenue Officer.

Oral Genome Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Oral Genome Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Oral Genome's valuation, stock price, and market status.

Firmographic Details

HeadquartersCarlsbad, California
Employee Range9
Year Founded2022
Last FundingJun 26, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?